Skip to content
B-LCL-CDG3
Tissue
Peripheral blood
Disease
Congenital Disorders of Glycosylation
Metastatic site
Not applicable (EBV-transformed B-LCL; non-metastatic)

Documents

B-LCL-CDG3

Cell line · Product number 302014

B-LCL-CDG3 is an EBV-transformed B lymphocyte cell line derived from a patient with PMM2-CDG, a congenital disorder of glycosylation (CDG) caused by mutat...

€800.00excl. tax and shipping

Customization / Recommendations

In stock
Lot
Recommended (freshest lot)
1

01General information

Description

B-LCL-CDG3 is an EBV-transformed B lymphocyte cell line derived from a patient with PMM2-CDG, a congenital disorder of glycosylation (CDG) caused by mutations in the *PMM2* gene. PMM2 encodes phosphomannomutase 2, a key enzyme in the N-glycosylation pathway, responsible for converting mannose-6-phosphate to mannose-1-phosphate. Deficiencies in PMM2 result in impaired glycosylation of multiple glycoproteins and glycolipids, leading to a broad spectrum of clinical manifestations, including neurological, hepatic, and endocrine dysfunction.

As an EBV-immortalized B cell line, B-LCL-CDG3 serves as a valuable in vitro model for studying the molecular effects of *PMM2* mutations. This cell line can be used to analyze glycosylation defects, investigate PMM2 enzyme activity, and test potential therapeutic strategies, such as enzyme enhancement therapies or substrate supplementation. B-LCL-CDG3, along with other CDG patient-derived cell models, contributes to advancing research on CDG pathophysiology and treatment development.

Tissue
Peripheral blood
Disease
Congenital Disorders of Glycosylation
Metastatic site
Not applicable (EBV-transformed B-LCL; non-metastatic)
Applications
Genotyping of CDG effects in immune cells, functional testing (e.g. B cell surface antigens), testing of cytotoxic drugs. Mutational analysis, analysis of apoptotic mechanisms, HLA-typing, impact of defective glycosylation of distinct cellular glycoproteins on diverse functions.

02Classification

Organism
Human
Sex
Female
Growth properties
Suspension
GMO status
GMO-S2
GMO status details
GMO-S2: This B-LCL contains a stably maintained EBV episome encoding viral latent-phase genes (EBNA-1/-2/-3, LMP-1/-2). EBV is classified as a risk group 2 pathogen; BSL-2 containment required. This classification applies within Germany; regulations may differ elsewhere.
Biosafety level
2

03Characteristics

Morphology
Round cells
Cell type
B lymphocyte

04Identifiers

Citation
B-LCL-CDG3 (Cytion catalog number 302014)
NCBI TaxID
9606
Cellosaurus
Not assigned

05Expression and susceptibility

Viruses
Transformant: EBV

06Handling and culture

Culture medium
RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a)
Incubation atmosphere

37°C, 5% CO2, humidified atmosphere.

Supplements
Supplement the medium with 10% heat-inactivated FBS
Subculturing
Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 2 x 105 cells/ml and keep the cell concentration within the range of 1 x 105 to 5 x 105 cells/ml for optimal growth.
Fluid renewal
Once the medium colour turned into yellow
Post-thaw recovery
Medium
Thawing and culturing
  1. Confirm that the vial remains deeply frozen upon delivery, as cells are shipped on dry ice to maintain optimal temperatures during transit.

  2. Upon receipt, either store the cryovial immediately at temperatures below -150°C to ensure the preservation of cellular integrity, or proceed to step 3 if immediate culturing is required.

  3. For immediate culturing, swiftly thaw the vial by immersing it in a 37°C water bath with clean water and an antimicrobial agent, agitating gently for 40-60 seconds until a small ice clump remains.

  4. Perform all subsequent steps under sterile conditions in a flow hood, disinfecting the cryovial with 70% ethanol before opening.

  5. Carefully open the disinfected vial and transfer the cell suspension into a 15 ml centrifuge tube containing 8 ml of room-temperature culture medium, mixing gently.

  6. Centrifuge the mixture at 300 x g for 3 minutes to separate the cells and carefully discard the supernatant containing residual freezing medium.

  7. Gently resuspend the cell pellet in 10 ml of fresh culture medium. For adherent cells, divide the suspension between two T25 culture flasks; for suspension cultures, transfer all the medium into one T25 flask to promote effective cell interaction and growth.

  8. Adhere to established subculture protocols for continued growth and maintenance of the cell line, ensuring reliable experimental outcomes.

07Quality control and cryopreservation

Sterility

Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods.

To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections.

Freeze medium
As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.
Storage conditions

For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen.

Shipping conditions

Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage.

08Donor

Ethnicity
Caucasian